{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '30', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '+3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Prior concomitant', 'medications received', 'within 30 days before the', 'first dose of study', 'Prior/concomitant', 'intervention through', 'X', 'medications', '30 days after the last', 'dose of study', 'intervention (or 90 days', 'if used to treat an SAE)', 'will be recorded.', 'Treatment', 'X', 'Dose within 3 days of', 'randomization', 'randomization.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '31', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', '1', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Study Intervention Administration', 'Pembrolizumab', 'X', 'X', 'X', 'X', 'X', 'Pembrolizumab 200 mg', 'administration', 'IV Q3W.', 'Tumor Scans', '*Perform Q9W', '(63=7 days) from', 'randomization through', 'Week 54, then Q12W', '(84 = 7 days)', 'Tumor scans and', 'subsequently (ie, after', 'Weeks 9, 18, 27, 36, 45,', 'response assessment', 'X*', 'X', '54, 66, 78, 90, etc.).', '(thorax, abdomen,', 'Schedule should be', 'pelvis)', 'followed regardless of', 'treatment delays.', '- -If imaging was obtained', 'within 4 weeks before', 'DC, scan at DC is not', 'mandatory.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '32', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', '-Required at screening.', '-Follow-up MRI is', 'required if clinically', 'indicated and at time of', 'CR in participants with', 'brain metastasis at', 'Brain MRI', 'X', 'Screening.', '-If MRI is', 'contraindicated or cannot', 'be performed, CT of the', 'head with contrast is', 'acceptable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}